Closed malachig closed 6 years ago
Adding an "evidence type" field is obviously pretty straightforward. I am curious though, how similar will these new evidence records be to our existing ones?
Some fields will obviously be common between "types" (say the evidence statement, or the disease). Other fields (the obvious example being "source") will be pretty different depending on the evidence type.
Will they be distinct enough that we should introduce a different evidence record schema for each "type" or does it make more sense to tack on extra fields as needed and expand the notion of what constitutes a valid "source?"
For ClinVar we need a few examples to use as prototypes. Start with the idea that a ClinVar variant record could be analogous to a pubmed indexed publication. Could we treat it similarly and create one or more evidence records in CIViC? How forced does that seem? Does it fit the CIViC data model close enough for us to move forward with ClinVar as a new evidence source type.
To identify some examples we might start with the 4-star ClinVar entries: Advanced search: "practice guideline"[Review status]
During the NKI meeting, European clinical trials were mentioned to me. I know even less about accessing these as I do US trials but I was pointed to the following search page. This is probably worth digging into as well. It would be great if we could support these. https://www.clinicaltrialsregister.eu/ctr-search/search?query=olaparib
We should also accept biorxiv.
ASCO abstracts are now here: http://abstracts.asco.org/
Example ASCO abstract to be submitted to CIViC. https://meetinglibrary.asco.org/record/145472/abstract
Example ASCO API queries:
Presentation record example: https://ml-couch.asco.org/records/148577
Abstract example: https://ml-couch.asco.org/abstracts/148577
Then to get a list of all the unique IDs: https://ml-couch.asco.org/abstracts/_all_docs https://ml-couch.asco.org/records/_all_docs
From these we could get all the author, title, citation info we need and create a link back to ASCO University any time we are discussing an abstract by creating a URL like this: https://meetinglibrary.asco.org/record/148577/abstract
Issue moved to griffithlab/civic-client #976 via ZenHub
Above are examples of how these are formatted in publications, and what people will be using to look for them
Moved to the civic-client repo for better organization.
Currently CIViC only allows evidence that corresponds to peer reviewed publication indexed by PubMed.
There are at least two other categories of sources that have been proposed:
There are two main motivations for allowing this:
This is a high level decision for CIViC. Should the scope of CIViC be absolutely limited to peer-reviewed published evidence? Or is CIViC a place to document evidence that has reached a threshold that is high enough to influence clinical practice (which is not exclusively represented by publication).
From the CIViC meeting at NKI, it seems clear that for predisposing germline variants, a publication is not a hard requirement. Publications are considered but so is evidence published in resources like ClinVar. If that evidence is strong enough, a predisposing variant interpretation will be returned to patients even when there is not a body of evidence in peer reviewed publications documented in PubMed.
CIViC could be a place where this evidence could be discussed and the final interpretation debated by the community. Feedback from the NKI meeting suggested that this could be a very valuable resource to the community and might allow us to engage a new (and large) user base of clinical pathologists.